# Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin

Study · id `cardio:ct-nct05504239` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05504239](<https://clinicaltrials.gov/study/NCT05504239>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05504239

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 235 participants.

## Technical summary

Registry record NCT05504239. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-27 (actual); primary completion 2024-04-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 235 participants (enrolled count; ClinicalTrials.gov record NCT05504239, source copy `cardio:ctgov-nct05504239-2025-01-24`, retrieved 2026-10-26)
- Started: 2022-09-27 (actual) (ClinicalTrials.gov record NCT05504239, source copy `cardio:ctgov-nct05504239-2025-01-24`, retrieved 2026-10-26)
- Primary completion: 2024-04-23 (actual) (ClinicalTrials.gov record NCT05504239, source copy `cardio:ctgov-nct05504239-2025-01-24`, retrieved 2026-10-26)
- Completion: 2024-04-23 (actual) (ClinicalTrials.gov record NCT05504239, source copy `cardio:ctgov-nct05504239-2025-01-24`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05504239, source copy `cardio:ctgov-nct05504239-2025-01-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05504239-2025-01-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin
- Acronym: TERA 304
- Condition: Type 2 Diabetes
- Intervention (Drug): Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet
- Intervention (Drug): Teneligliptin Placebo Oral Tablet
- Lead sponsor: Handok Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Handok Inc. (`cardio:org-handok-inc`)

## Provenance

Content hash: e4acd41eecccbdd097ab94a1d1480774c55b879cfa2ac45135a58d26d8aa9219
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
